5-amino-4-(6-methyl-1H-benzimidazol-2-yl)-1-(2-methylpropyl)-2H-pyrrol-3-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 5-amino-4-(6-methyl-1H-benzimidazol-2-yl)-1-(2-methylpropyl)-2H-pyrrol-3-one
• 化学式: C₁₆H₂₀N₄O
• 分子量: 284.36
• InChiKey: GGOKCMCHGBPIKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  75
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect
  申请人：Friedrich-Alexander-Universität Erlangen-Nürnberg

  公开号：US10828281B2

  公开（公告）日：2020-11-10

  The present invention is directed to compounds, tautomers, stereoisomers, and chemically modified compounds thereof, and their use in preventing and/or treating tumors of metastasis and/or cartilage defect, and to a pharmaceutical composition comprising such compound.

  本发明涉及其化合物、同系物、立体异构体和化学修饰化合物，及其在预防和/或治疗肿瘤转移和/或软骨缺损中的用途，以及包含此类化合物的药物组合物。
• ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
  申请人：Magenta Therapeutics Inc.

  公开号：US20210220408A1

  公开（公告）日：2021-07-22

  The disclosure relates to aryl hydrocarbon receptor antagonists as well as methods of modulating aryl hydrocarbon receptor activity and expanding hematopoietic stem cells by culturing hematopoietic stem or progenitor cells in the presence of these agents. Additionally, the disclosure provides methods of treating various pathologies, such as cancer, by administration of these aryl hydrocarbon receptor antagonists. Additionally, the disclosure provides methods of treating various pathologies in a patient by administration of expanded hematopoietic stem cells. The disclosure further provides kits containing aryl hydrocarbon receptor antagonists that can be used for the expansion of hematopoietic stem cells. The disclosure further relates to pharmaceutical compositions comprising the compounds and methods of treating or preventing a disease in which aryl hydrocarbon receptor plays a role.